{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:58:37Z","timestamp":1753891117543,"version":"3.41.2"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872102"],"award-info":[{"award-number":["81872102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Several studies have found that pathological imbalance of alterative splicing (AS) events is associated with cancer susceptibility. carcinogenicity. Nevertheless, the relationship between heritable variation in AS events and carcinogenicity has not been extensively explored. Here, we downloaded AS event signatures, transcriptome profiles, and matched clinical information from The Cancer Genome Atlas (TCGA) database, identified the prognostic AS-related events <jats:italic>via<\/jats:italic> conducting the univariate Cox regression algorism. Subsequently, the prognostic AS-related events were further reduced by the least absolute shrinkage and selection operator (LASSO) logistic regression model, and employed for constructing the risk model. Single-sample (ssGSEA), ESTIMATE, and the CIBERSORT algorithms were conducted to evaluate tumor microenvironment status. CCK8, cell culture scratch, transwell invasion assays and flow cytometry were conducted to confirm the reliability of the model. We found 2751 prognostic-related AS events, and constructed a risk model with seven prognostic-related AS events. Compared with high-risk score patients, the overall survival rate of the patients with low-risk score was remarkably longer. Besides, we further found that risk score was also closely related to alterations in immune cell infiltration and immunotherapeutic molecules, indicating its potential as an observation of immune infiltration and clinical response to immunotherapy. In addition, the downstream target gene (DYM) could be a promising prognostic factor for bladder cancer. Our investigation provided an indispensable reference for ulteriorly exploring the role of AS events in the tumor microenvironment and immunotherapy efficiency, and rendered personalized prognosis monitoring for bladder cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2022.911902","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:58:09Z","timestamp":1655096289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Fangdie","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What Is the Significance of Variant Histology in Urothelial Carcinoma","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.010","article-title":"Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset","volume":"72","author":"Choi","year":"2017","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-Invasive Bladder Cancer on Predicting Response and Survival After Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular Subtypes of Bladder Cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.eururo.2019.01.011","article-title":"Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.7150\/jca.28494","article-title":"Multi-Omics Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer","volume":"10","author":"Chen","year":"2019","journal-title":"J Canc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3400","article-title":"Immune-Related Signature Predicts the Prognosis and Immunotherapy Benefit in Bladder Cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy With CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG Immunotherapy and its Outlook for Bladder Cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S158753","article-title":"Immune Checkpoint Inhibitors in Urothelial Cancer: Recent Updates and Future Outlook","volume":"14","author":"Gopalakrishnan","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.27","article-title":"Alternative Splicing as a Regulator of Development and Tissue Identity","volume":"18","author":"Baralle","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.canlet.2017.02.016","article-title":"Prognostic Alternative mRNA Splicing Signature in non-Small Cell Lung Cancer","volume":"393","author":"Li","year":"2017","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.318","article-title":"Aberrant RNA Splicing in Cancer; Expression Changes and Driver Mutations of Splicing Factor Genes","volume":"35","author":"Sveen","year":"2016","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.012","article-title":"The Functional Impact of Alternative Splicing in Cancer","volume":"20","author":"Climente-Gonz\u00e1lez","year":"2017","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4165","article-title":"Therapeutic Targeting of Splicing in Cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1970-0","article-title":"Genomic Basis for RNA Alterations in Cancer","volume":"578","author":"Calabrese","year":"2020","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.08.011","article-title":"The Nuclear-Retained Noncoding RNA MALAT1 Regulates Alternative Splicing by Modulating SR Splicing Factor Phosphorylation","volume":"39","author":"Tripathi","year":"2010","journal-title":"Mol Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2017.03.013","article-title":"Splicing Factors of SR and hnRNP Families as Regulators of Apoptosis in Cancer","volume":"396","author":"K\u0119dzierska","year":"2017","journal-title":"Cancer Lett"},{"key":"B21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2020.11.043","article-title":"Splicing Factors: Insights Into Their Regulatory Network in Alternative Splicing in Cancer","volume":"501","author":"Du","year":"2021","journal-title":"Cancer Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051551","article-title":"Roles of Splicing Factors in Hormone-Related Cancer Progression","volume":"21","author":"Takeiwa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23207","article-title":"Alternative Splicing Related Genetic Variants Contribute to Bladder Cancer Risk","volume":"59","author":"Guo","year":"2020","journal-title":"Mol Carcinogen"},{"key":"B24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ymthe.2020.08.018","article-title":"NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR","volume":"29","author":"Xie","year":"2021","journal-title":"Mol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2019.01.041","article-title":"Polypyrimidine Tract Binding Protein 1 Promotes Lymphatic Metastasis and Proliferation of Bladder Cancer via Alternative Splicing of MEIS2 and PKM","volume":"449","author":"Xie","year":"2019","journal-title":"Cancer Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3850","article-title":"The Splicing Factor PTBP1 Promotes Expression of Oncogenic Splice Variants and Predicts Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer","volume":"24","author":"Bielli","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1964252","article-title":"Identification of Prognostic and Bone Metastatic Alternative Splicing Signatures in Bladder Cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Bioengineered"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust Enumeration of Cell Subsets From Tissue Expression Profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721030","article-title":"Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0208-0","article-title":"Molecular and Histopathology Directed Therapy for Advanced Bladder Cancer","volume":"16","author":"Alifrangis","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3518-7","article-title":"Role of Immunotherapy in Bladder Cancer: Past, Present and Future","volume":"81","author":"Butt","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/path.5306","article-title":"Bladder Cancer, a Unique Model to Understand Cancer Immunity and Develop Immunotherapy Approaches","volume":"249","author":"Song","year":"2019","journal-title":"J Pathol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin Immunotherapy for Bladder Cancer: A Review of Immunological Aspects, Clinical Effects and BCG Infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS Acta Patholo Microbiol Immuno Scandin"},{"key":"B36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","article-title":"A Review on the Evolution of PD-1\/PD-L1 Immunotherapy for Bladder Cancer: The Future is Now","volume":"54","author":"Bellmunt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nature08909","article-title":"Expansion of the Eukaryotic Proteome by Alternative Splicing","volume":"463","author":"Nilsen","year":"2010","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.017","article-title":"Alternative Splicing Regulatory Networks: Functions, Mechanisms, and Evolution","volume":"76","author":"Ule","year":"2019","journal-title":"Mol Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2666","article-title":"Role of Alternative Splicing Signatures in the Prognosis of Glioblastoma","volume":"8","author":"Xie","year":"2019","journal-title":"Cancer Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.18632\/aging.101902","article-title":"Role of Global Aberrant Alternative Splicing Events in Papillary Thyroid Cancer Prognosis","volume":"11","author":"Lin","year":"2019","journal-title":"Aging"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-012-0082-8","article-title":"Discovery of TP53 Splice Variants in Two Novel Papillary Urothelial Cancer Cell Lines","volume":"35","author":"Koch","year":"2012","journal-title":"Cell Oncol (Dordrecht)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10362","DOI":"10.1038\/s41598-019-46652-4","article-title":"Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status","volume":"9","author":"Due\u00f1as","year":"2019","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10585-015-9754-x","article-title":"Urinary Oncofetal ED-A Fibronectin Correlates With Poor Prognosis in Patients With Bladder Cancer","volume":"33","author":"Arnold","year":"2016","journal-title":"Clin Exp Metasta"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626858","article-title":"Genome-Wide Analyses of Prognostic and Therapeutic Alternative Splicing Signatures in Bladder Urothelial Carcinoma","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-34025-4_13","article-title":"Inflammatory Microenvironment Modulation of Alternative Splicing in Cancer: A Way to Adapt","volume":"1219","author":"Silva","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7150\/thno.36585","article-title":"Comprehensive Characterization of the Alternative Splicing Landscape in Head and Neck Squamous Cell Carcinoma Reveals Novel Events Associated With Tumorigenesis and the Immune Microenvironment","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21413","article-title":"Dymeclin, the Gene Underlying Dyggve-Melchior-Clausen Syndrome, Encodes a Protein Integral to Extracellular Matrix and Golgi Organization and is Associated With Protein Secretion Pathways Critical in Bone Development","volume":"32","author":"Denais","year":"2011","journal-title":"Hum Mutat"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2598","article-title":"Tumor Purity as an Underlying Key Factor in Glioma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/2326-6066.CIR-17-0201","article-title":"Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses Across Multiple Cancer Types","volume":"6","author":"Rhee","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01101","article-title":"Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors","volume":"9","author":"Pan","year":"2019","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T04:58:13Z","timestamp":1655096293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2022.911902"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.911902","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"article-number":"911902"}}